Ubs Group Ag Immuno Gen, Inc. Call Options Transaction History

Ubs Group Ag

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$12.46 - $29.95 $684,054 - $1.64 Million	54,900 Added 41.03%	188,700 $5.59 Million
Q3 2023 Nov 09, 2023	BUY	$14.09 - $19.87 $70,450 - $99,350	5,000 Added 3.88%	133,800 $2.12 Million
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $483,000 - $2.58 Million	128,800 New	128,800 $2.43 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.